Anita Bellail
Chief Executive Officer HB Therapeutics, Inc.
Anita Bellail is Co-Founder of HB Therapeutics and a recognized leader in targeted protein degradation and molecular glue discovery. Alongside her academic research at Indiana University School of Medicine, she has pioneered molecular glue platforms and contributed to the discovery of novel degraders targeting disease-driving proteins. Her work bridges fundamental biology, translational research, and therapeutic development.
Seminars
Wednesday 27th January 2027
Chair’s Opening Remarks
8:50 am
Wednesday 27th January 2027
Harnessing Endogenous Ligases to Expand the Reach of Molecular Glue Degradation
1:30 pm
- Developing molecular glue degraders that leverage endogenous ligases beyond cereblon, expanding the range of induced-proximity mechanisms available for targeted protein degradation
- Applying novel ligase biology to challenging targets including KRAS and SREBF, unlocking therapeutic opportunities against proteins that have traditionally proven difficult to drug
- Establishing a new framework for molecular glue discovery beyond cereblon-dependent approaches, broadening the degrader toolbox and enabling the next generation of targeted therapies
Wednesday 27th January 2027
Chair’s Closing Remarks
5:00 pm
